- Home
- TYRA
TYRA
Tyra Biosciences Inc.
as 03-28-2025 4:00pm EST
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CARLSBAD |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $30.50 | AVG Volume (30 days): | 331.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.49 - $29.60 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tyra Biosciences Inc. (TYRA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kjellson Nina S | TYRA | Director | Feb 5 '25 | Sell | $13.76 | 5,401 | $74,323.70 | 3,700,705 | |
| Kjellson Nina S | TYRA | Director | Jan 23 '25 | Sell | $16.26 | 4,825 | $78,466.08 | 3,700,705 | |
| Kjellson Nina S | TYRA | Director | Jan 16 '25 | Sell | $16.35 | 25,041 | $409,645.36 | 3,700,705 |
Latest Tyra Biosciences Inc. News
TYRA Breaking Stock News: Dive into TYRA Ticker-Specific Updates for Smart Investing
PR Newswire
a day ago
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights
PR Newswire
a month ago
Tyra Biosciences to Present at Upcoming Investor Conferences
PR Newswire
2 months ago
Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors
Simply Wall St.
2 months ago
Private equity firms account for 44% of Tyra Biosciences, Inc.'s (NASDAQ:TYRA) ownership, while institutions account for 33%
PR Newswire
2 months ago
Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers Symposium
MT Newswires
2 months ago
Tyra Biosciences Insider Sold Shares Worth $409,645, According to a Recent SEC Filing
MT Newswires
3 months ago
Tyra Biosciences' TYRA-300 Gets US FDA Clearance for Phase 2 Trial in Non-Muscle Invasive Bladder Cancer
PR Newswire
3 months ago
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Compare TYRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TYRA Tyra Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.